The development of broad-spectrum antitumor agents with anti-HMGB1 antibody and clarification of its action mechanism

渗透泵连续给药抗HMGB1抗体7天显著降低小鼠肿瘤移植模型中的肿瘤生长，而相同剂量的抗KLH抗体（对照）对肿瘤生长没有影响。在用抗HMGB1抗体处理的组中，与用抗KLH抗体处理的数目相比，肿瘤组织中的CD31阳性血管的数目显著减少。然而，在使用免疫缺陷小鼠的肿瘤移植模型中，抗HMGB1抗体的施用对肿瘤生长没有影响。这些数据表明，抗HMGB1抗体不是直接而是通过免疫应答减少肿瘤生长。

The osmotic pump continuous dosing of anti-HMGB1 antibody for 7 days significantly reduced tumor growth in mouse tumor graft model, whereas the same dose of anti-KLH antibody (control) had no effect on tumor growth. In the group treated with anti-HMGB1 antibody, the number of CD31-positive blood vessel in tumor tissue was significantly decreased in comparison with the number by treatment with anti-KLH antibody. However, the administration of anti-HMGB1 antibody had no effect on tumor growth in tumor graft model using immune-deficient mice. These data suggested that anti-HMGB1 antibody reduced tumor growth not directly but through immune response.